

Recent progress in the diagnosis and treatment of ovarian

Ca-A Cancer Journal for Clinicians

61, 183-203

DOI: [10.3322/caac.20113](https://doi.org/10.3322/caac.20113)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Long-Term Survival of Women With Epithelial Ovarian Cancer Detected by Ultrasonographic Screening. <i>Obstetrics and Gynecology</i> , 2011, 118, 1212-1221.	1.2	102
3	The validity of self-reported dental agenesis. <i>European Journal of Oral Sciences</i> , 2011, 119, 282-287.	0.7	2
4	Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. <i>Biomaterials</i> , 2011, 32, 8548-8554.	5.7	164
6	Pemetrexed disodium in ovarian cancer treatment. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 437-449.	1.9	7
8	Heterotypic Three-dimensional <i>In Vitro</i> Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression. <i>Journal of Visualized Experiments</i> , 2012, , e4206.	0.2	14
9	Effect of the combination of a cyclooxygenase-1 selective inhibitor and taxol on proliferation, apoptosis and angiogenesis of ovarian cancer <i>in vivo</i> . <i>Oncology Letters</i> , 2012, 4, 168-174.	0.8	16
10	Ovarian Cancer Screening. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 43-51.	0.6	32
11	Clinical implications of pleural effusions in ovarian cancer. <i>Respirology</i> , 2012, 17, 1060-1067.	1.3	34
12	Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOVE pilot project. <i>Lancet Oncology</i> , The, 2012, 13, 285-291.	5.1	129
13	Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012, 127, 70-74.	0.6	61
14	HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. <i>Tumor Biology</i> , 2012, 33, 1291-1298.	0.8	22
15	Palliative Chemotherapy for Malignant Ascites Secondary to Ovarian Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2012, 29, 515-521.	0.8	15
16	Primary cilia and aberrant cell signaling in epithelial ovarian cancer. <i>Cilia</i> , 2012, 1, 15.	1.8	72
17	Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma. <i>Journal of Biomedical Research</i> , 2012, 26, 274.	0.7	3
18	Reproductive factors in relation to ovarian cancer: a case-control study in Northern Vietnam. <i>Contraception</i> , 2012, 86, 494-499.	0.8	17
19	Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer. <i>Journal of Proteome Research</i> , 2012, 11, 4605-4614.	1.8	48
20	Ovarian cancer molecular pathology. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 713-732.	2.7	57
21	Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2012, 7, e52745.	1.1	22

#	ARTICLE	IF	CITATIONS
22	Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. <i>Journal of Oncology</i> , 2012, 2012, 1-23.	0.6	39
23	Modern Trends into the Epidemiology and Screening of Ovarian Cancer. Genetic Substrate of the Sporadic Form. <i>Pathology and Oncology Research</i> , 2012, 18, 135-148.	0.9	9
24	Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. <i>Journal of Controlled Release</i> , 2012, 158, 386-392.	4.8	123
25	RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. <i>Gynecologic Oncology</i> , 2012, 124, 589-597.	0.6	12
26	Mucoadhesive hybrid gel improves intraperitoneal platinum delivery. <i>International Journal of Pharmaceutics</i> , 2013, 458, 148-155.	2.6	7
27	Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells. <i>International Journal of Pharmaceutics</i> , 2013, 458, 169-180.	2.6	68
28	Biomarkers for Early Detection of Ovarian Cancer. <i>Women's Health</i> , 2013, 9, 171-187.	0.7	53
29	Targeting tyrosine-kinases in ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1265-1279.	1.9	23
30	Estimating the proportion cured of cancer: Some practical advice for users. <i>Cancer Epidemiology</i> , 2013, 37, 836-842.	0.8	40
31	Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2347-2359.	1.1	24
32	Characterization and proteomic analysis of ovarian cancer-derived exosomes. <i>Journal of Proteomics</i> , 2013, 80, 171-182.	1.2	254
33	Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 655-666.	0.8	22
34	Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. <i>Biomaterials</i> , 2013, 34, 4068-4077.	5.7	54
35	Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: A Korean Gynecologic Oncology Group study (KGOG-3022). <i>Gynecologic Oncology</i> , 2013, 131, 336-340.	0.6	8
36	Stromalâ€œEpithelial Crosstalk Provides a Suitable Microenvironment for the Progression of Ovarian Cancer Cells<i>in Vitro</i>. <i>Cancer Investigation</i> , 2013, 31, 616-624.	0.6	7
37	Targeted therapies and clinical trials in ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, x59-x63.	0.6	11
38	Angiogenesis as a target for the treatment of ovarian cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 558-565.	1.1	25
39	Sorafenib for ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1049-1062.	1.9	18

#	ARTICLE	IF	CITATIONS
40	Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. <i>Cancer Medicine</i> , 2013, 2, 751-762.	1.3	46
41	TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. <i>Cell Cycle</i> , 2013, 12, 511-521.	1.3	90
42	Urokinase Plasminogen Activator Systemâ€”Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2628-2639.	1.9	34
43	Transvaginal ultrasonography in ovarian cancer screening: current perspectives. <i>International Journal of Women's Health</i> , 2013, 6, 25.	1.1	45
44	Vascular endothelial growth factor +936C/T polymorphism and cancer risk in Asians: a meta-analysis. <i>Genetics and Molecular Research</i> , 2013, 12, 1924-1933.	0.3	4
45	Early detection of ovarian cancer. , 0, , 355-380.		0
46	Development of Nanoscale Approaches for Ovarian Cancer Therapeutics and Diagnostics. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, 281-315.	0.2	37
47	The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e89841.	1.1	20
48	Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. <i>Epigenetics</i> , 2014, 9, 1577-1587.	1.3	32
49	Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model. <i>EJNMMI Research</i> , 2014, 4, 54.	1.1	13
50	EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. <i>Cancer Biology and Therapy</i> , 2014, 15, 271-278.	1.5	27
51	High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 402-410.	0.9	45
52	Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1 α pathway in human ovarian cancer in vitro. <i>Journal of Ovarian Research</i> , 2014, 7, 115.	1.3	21
53	Sphingosine 1-phosphate: A Potential Molecular Target for Ovarian Cancer Therapy?. <i>Cancer Investigation</i> , 2014, 32, 71-80.	0.6	26
54	Specific cell targeting with APRPG conjugated PEGâ€”PLGA nanoparticles for treating ovarian cancer. <i>Biomaterials</i> , 2014, 35, 983-992.	5.7	49
55	Metabolomics in cell cultureâ€”A strategy to study crucial metabolic pathways in cancer development and the response to treatment. <i>Archives of Biochemistry and Biophysics</i> , 2014, 564, 100-109.	1.4	67
56	Magnetic mesoporous silica nanoparticles for potential delivery of chemotherapeutic drugs and hyperthermia. <i>Dalton Transactions</i> , 2014, 43, 15482-15490.	1.6	102
57	AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 325-332.	0.6	28

#	ARTICLE	IF	CITATIONS
58	Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2081-2091.	1.9	28
59	Ovarian and oviductal pathologies in the buffalo: Occurrence, diagnostic and therapeutic approaches. <i>Asian Pacific Journal of Reproduction</i> , 2014, 3, 156-168.	0.2	6
60	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2014, , 1257-1268.		0
61	Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1041-1050.	1.1	4
62	Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases. <i>Frontiers of Medicine</i> , 2014, 8, 91-95.	1.5	8
63	Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells. <i>Clinical and Translational Oncology</i> , 2014, 16, 898-905.	1.2	23
64	Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. <i>Journal of Controlled Release</i> , 2014, 174, 161-170.	4.8	173
65	Cisplatin- α -alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. <i>Biomaterials</i> , 2014, 35, 4297-4309.	5.7	101
66	TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 752-757.	0.6	32
67	Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy. <i>Acta Biomaterialia</i> , 2014, 10, 2965-2975.	4.1	58
68	MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. <i>FEBS Letters</i> , 2014, 588, 1608-1615.	1.3	41
69	Lived experiences of women with recurring ovarian cancer. <i>European Journal of Oncology Nursing</i> , 2014, 18, 104-109.	0.9	14
70	Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2014, 34, 515-518.	0.4	54
71	MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1. <i>Biochemical and Biophysical Research Communications</i> , 2014, 449, 432-437.	1.0	47
72	Ovarian cancer. <i>Lancet, The</i> , 2014, 384, 1376-1388.	6.3	1,491
73	The emerging role of anti-angiogenic therapy in ovarian cancer. <i>International Journal of Oncology</i> , 2014, 44, 1417-1424.	1.4	18
74	Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF- β 2 signaling pathway. <i>International Journal of Oncology</i> , 2014, 44, 1099-1106.	1.4	31
75	BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer. <i>Medicine (United States)</i> , 2015, 94, e1695.	0.4	7

#	ARTICLE	IF	CITATIONS
76	Role of Aurora-A in Ovarian Cancer: A Meta-Analysis. <i>Oncology Research and Treatment</i> , 2015, 38, 442-447.	0.8	2
77	Highly-accurate metabolomic detection of early-stage ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 16351.	1.6	65
78	RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells. <i>Molecular Medicine Reports</i> , 2015, 12, 6635-6641.	1.1	10
79	Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3 in vitro. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 579-583.	0.8	58
80	Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 146.	1.8	95
81	Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models. <i>BMC Cancer</i> , 2015, 15, 889.	1.1	18
82	Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. <i>International Journal of Nanomedicine</i> , 2015, 10, 2579.	3.3	43
83	GOLPH3L is a Novel Prognostic Biomarker for Epithelial Ovarian Cancer. <i>Journal of Cancer</i> , 2015, 6, 893-900.	1.2	16
84	Research Progress of MicroRNA in Early Detection of Ovarian Cancer. <i>Chinese Medical Journal</i> , 2015, 128, 3363-3370.	0.9	21
85	Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration. <i>PLoS ONE</i> , 2015, 10, e0142157.	1.1	19
86	Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition. <i>PLoS ONE</i> , 2015, 10, e0143659.	1.1	23
87	A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0144126.	1.1	36
88	MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL. <i>Tumor Biology</i> , 2015, 36, 7277-7283.	0.8	32
89	Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach. <i>Cancer Letters</i> , 2015, 359, 233-240.	3.2	31
90	Evaluation of ^{99m} Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT. <i>Nuclear Medicine and Biology</i> , 2015, 42, 256-262.	0.3	28
91	The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. <i>Gynecologic Oncology</i> , 2015, 137, 125-133.	0.6	58
92	MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition. <i>Tumor Biology</i> , 2015, 36, 4261-4269.	0.8	13
93	Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1341-1348.	0.7	36

#	ARTICLE	IF	CITATIONS
95	Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2015, 139, 355-362.	0.6	58
96	Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. <i>JAMA Oncology</i> , 2015, 1, 737.	3.4	38
97	Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy. <i>Journal of Materials Chemistry B</i> , 2015, 3, 6310-6326.	2.9	61
98	Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150109.	1.0	7
99	Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. <i>International Immunology</i> , 2015, 27, 621-632.	1.8	30
100	Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. <i>Molecular Medicine Reports</i> , 2015, 12, 3249-3256.	1.1	25
101	EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. <i>Pharmaceutical Research</i> , 2015, 32, 2753-63.	1.7	24
102	Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 351-364.	1.6	23
103	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1495-1504.	2.0	51
104	Butein Shows Cytotoxic Effects and Induces Apoptosis in Human Ovarian Cancer Cells. <i>The American Journal of Chinese Medicine</i> , 2015, 43, 769-782.	1.5	25
105	Identification of candidate biomarker mass (m/z) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. <i>Biomarkers</i> , 2015, 20, 292-298.	0.9	9
106	Elevated β -catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 173-178.	1.0	34
107	Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. <i>International Journal of Pharmaceutics</i> , 2015, 496, 1026-1033.	2.6	45
108	Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness. <i>Journal of Surgical Research</i> , 2015, 193, 255-264.	0.8	59
109	The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 207-218.	1.7	66
110	Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. <i>Biomaterials</i> , 2015, 37, 312-319.	5.7	74
111	LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. <i>Human Molecular Genetics</i> , 2015, 24, 841-852.	1.4	157
112	Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo. <i>OncoTargets and Therapy</i> , 2016, 9, 2365.	1.0	21

#	ARTICLE	IF	CITATIONS
113	Genomics-Guided Immunotherapy of Human Epithelial Ovarian Cancer. , 2016, , 237-250.		1
114	Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis. <i>OncoTargets and Therapy</i> , 2016, 9, 1559.	1.0	28
115	Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-11.	0.5	20
116	Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1387.	1.8	18
117	Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166058.	1.1	35
118	Surgical management of ovarian cancer. <i>Journal of the Korean Medical Association</i> , 2016, 59, 167.	0.1	2
119	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. <i>British Journal of Cancer</i> , 2016, 115, 228-235.	2.9	23
120	Identification of stably expressed reference small non-coding <i>scRNA</i> s for micro <i>scRNA</i> quantification in high-grade serous ovarian carcinoma tissues. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2341-2348.	1.6	50
121	Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases. <i>Cell Death and Disease</i> , 2016, 7, e2565-e2565.	2.7	39
122	Dysregulated Expression of Long Noncoding RNAs in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1564-1570.	1.2	50
123	Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. <i>International Journal of Oncology</i> , 2016, 49, 1945-1952.	1.4	31
124	Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 608-615.	0.6	7
125	Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. <i>Cancer Gene Therapy</i> , 2016, 23, 229-234.	2.2	23
126	Design, Synthesis, and Characterization of Folate-Targeted Platinum-Loaded Theranostic Nanoemulsions for Therapy and Imaging of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2016, 13, 1996-2009.	2.3	29
127	SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis. <i>Oncology Reports</i> , 2016, 35, 1796-1806.	1.2	24
128	Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis. <i>Thoracic Cancer</i> , 2016, 7, 39-43.	0.8	14
129	Alternating electric fields (TFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2016, 139, 2850-2858.	2.3	54
130	Ovarian and tubal cancer in Denmark: an update on incidence and survival. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 1181-1189.	1.3	20

#	ARTICLE	IF	CITATIONS
131	Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. <i>Clinical Cancer Research</i> , 2016, 22, 5909-5914.	3.2	78
132	Being a caregiver to patients with ovarian cancer: A scoping review of the literature. <i>Gynecologic Oncology</i> , 2016, 143, 184-192.	0.6	18
133	Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase. <i>Tumor Biology</i> , 2016, 37, 12263-12271.	0.8	13
134	The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins. <i>Tumor Biology</i> , 2016, 37, 13279-13286.	0.8	41
135	Plasma long non-coding RNA MALAT1 is associated with distant metastasis in patients with epithelial ovarian cancer. <i>Oncology Letters</i> , 2016, 12, 1361-1366.	0.8	48
136	Olaparib for the treatment of BRCA-mutated advanced ovarian cancer. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1037-1041.	0.5	21
137	Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer. <i>Medical Oncology</i> , 2016, 33, 126.	1.2	63
138	MPTOG066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis and potentiates antineoplastic effect of cisplatin in ovarian cancer. <i>Scientific Reports</i> , 2016, 6, 31664.	1.6	12
139	Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. <i>Journal of Ovarian Research</i> , 2016, 9, 55.	1.3	29
140	Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. <i>Scientific Reports</i> , 2016, 6, 26001.	1.6	42
141	Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers. <i>Scientific Reports</i> , 2016, 6, 29831.	1.6	53
142	Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1571-1579.	1.2	13
143	Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S38204.	0.6	14
144	The Role of Completion Surgery in Ovarian Cancer. <i>Journal of Obstetrics and Gynecology of India</i> , 2016, 66, 435-440.	0.3	1
145	Preparation of magnetic mesoporous silica nanoparticles as a multifunctional platform for potential drug delivery and hyperthermia. <i>Science and Technology of Advanced Materials</i> , 2016, 17, 229-238.	2.8	61
146	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. <i>Life Sciences</i> , 2016, 159, 49-54.	2.0	13
147	Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. <i>Journal of Controlled Release</i> , 2016, 226, 148-167.	4.8	42
148	Mind-body health in the school environment. <i>International Journal of School and Educational Psychology</i> , 2016, 4, 3-4.	1.0	2

#	ARTICLE	IF	CITATIONS
149	miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 57-70.	1.1	40
150	A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. <i>American Journal of Preventive Medicine</i> , 2016, 50, 384-394.	1.6	131
151	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 404-413.	3.3	47
152	Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 110-116.	0.6	8
153	Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 175-177.	0.6	13
154	Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. <i>Oncogenesis</i> , 2017, 6, e295-e295.	2.1	54
155	Potential Application of Dual-Energy CT in Gynecologic Cancer: Initial Experience. <i>American Journal of Roentgenology</i> , 2017, 208, 695-705.	1.0	30
156	TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. <i>Cancer Letters</i> , 2017, 393, 60-67.	3.2	77
157	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 100-121.	157.7	529
158	Overexpression of salusin- β is associated with poor prognosis in ovarian cancer. <i>Oncology Reports</i> , 2017, 37, 1826-1832.	1.2	6
159	Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer. <i>Medical Oncology</i> , 2017, 34, 87.	1.2	9
160	Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells. <i>International Journal of Oncology</i> , 2017, 50, 1279-1288.	1.4	10
161	Impact of community disadvantage and air pollution burden on geographic disparities of ovarian cancer survival in California. <i>Environmental Research</i> , 2017, 156, 388-393.	3.7	34
162	Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells. <i>Chemical Biology and Drug Design</i> , 2017, 90, 854-866.	1.5	7
163	Near-infrared mediated chemo/photodynamic synergistic therapy with DOX-UCNPs@mSiO ₂ /TiO ₂ -TC nanocomposite. <i>Materials Science and Engineering C</i> , 2017, 78, 998-1005.	3.8	35
164	A ¹⁹ F NMR probe for the detection of β -galactosidase: simple structure with low molecular weight of 274.2, α -turn-on-signal without the background, and good performance applicable in cancer cell line. <i>Journal of Materials Chemistry B</i> , 2017, 5, 4673-4678.	2.9	7
165	Capsaicin-loaded folic acid-conjugated lipid nanoparticles for enhanced therapeutic efficacy in ovarian cancers. <i>Biomedicine and Pharmacotherapy</i> , 2017, 91, 999-1005.	2.5	31
166	Long non-coding RNA MALAT1 is upregulated and involved in cell proliferation, migration and apoptosis in ovarian cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3055-3060.	0.8	35

#	ARTICLE	IF	CITATIONS
167	A Psychological Perspective on Factors Predicting Prophylactic Salpingo-oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations. <i>Journal of Genetic Counseling</i> , 2017, 26, 1144-1152.	0.9	6
168	Metal-Organic Framework/Graphene Quantum Dot Nanoparticles Used for Synergistic Chemo- and Photothermal Therapy. <i>ACS Omega</i> , 2017, 2, 1249-1258.	1.6	140
169	Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1107-1116.	1.2	38
170	Identification of a six-lncRNA signature associated with recurrence of ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 752.	1.6	52
171	TLR-exosomes exhibit distinct kinetics and effector function. <i>Scientific Reports</i> , 2017, 7, 41623.	1.6	19
172	Ovary Cancer Detection using Decision Tree Classifiers based on Historical Data of Ovary Cancer Patients. <i>IFMBE Proceedings</i> , 2017, , 503-510.	0.2	9
173	Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 303-314.	1.1	9
174	The long story of camptothecin: From traditional medicine to drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 701-707.	1.0	196
175	Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 1145-1152.	0.8	25
176	Exosomal delivery of berry anthocyanidins for the management of ovarian cancer. <i>Food and Function</i> , 2017, 8, 4100-4107.	2.1	127
177	Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. <i>Scientific Reports</i> , 2017, 7, 8090.	1.6	26
178	Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study. <i>Gynecologic Oncology</i> , 2017, 147, 98-103.	0.6	23
179	Should epithelial ovarian carcinoma metastatic to the inguinal lymph nodes be assigned stage IVB?. <i>Gynecologic Oncology</i> , 2017, 147, 81-84.	0.6	22
180	The Effect of Thymoquinone on Apoptosis of SK-OV-3 Ovarian Cancer Cell by Regulation of Bcl-2 and Bax. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1596-1601.	1.2	43
181	Obesity and ovarian cancer risk: A systematic review. <i>Post Reproductive Health</i> , 2017, 23, 183-198.	0.3	47
182	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. <i>Gynecologic Oncology</i> , 2017, 146, 484-490.	0.6	81
183	Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer. <i>Oncology Reports</i> , 2017, 38, 1464-1472.	1.2	24
184	Novel Intraperitoneal Treatment With Non-Thermal Plasma-Activated Medium Inhibits Metastatic Potential of Ovarian Cancer Cells. <i>Scientific Reports</i> , 2017, 7, 6085.	1.6	102

#	ARTICLE	IF	CITATIONS
185	CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth. <i>Anti-Cancer Drugs</i> , 2017, 28, 935-942.	0.7	29
186	Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. <i>Current Epidemiology Reports</i> , 2017, 4, 211-220.	1.1	56
187	Pyridoxine 5- α -phosphate oxidase is a novel therapeutic target and regulated by the TGF- β 2 signalling pathway in epithelial ovarian cancer. <i>Cell Death and Disease</i> , 2017, 8, 3214.	2.7	58
188	Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2017, 39, 676-685.	0.3	5
189	Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 948-966.	1.1	63
190	Celastrol inhibits migration and invasion through blocking the NF- κ B pathway in ovarian cancer cells. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 819-824.	0.8	22
191	Dasatinib+Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells. <i>Journal of Ovarian Research</i> , 2017, 10, 31.	1.3	13
192	The sL1CAM in sera of patients with endometrial and ovarian cancers. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 225-232.	0.8	5
193	Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. <i>Pharmacogenomics Journal</i> , 2017, 17, 506-514.	0.9	16
194	Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e381-e388.	0.7	10
195	Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. <i>Oncogene</i> , 2017, 36, 1537-1545.	2.6	49
196	Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in in vitro and in vivo . <i>Oncology Letters</i> , 2017, 15, 3233-3239.	0.8	6
197	Long non-coding RNA CCAT2 promotes epithelial-mesenchymal transition involving Wnt/ β -catenin pathway in epithelial ovarian carcinoma cells. <i>Oncology Letters</i> , 2017, 15, 3369-3375.	0.8	20
198	Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study. <i>Journal of Cancer</i> , 2017, 8, 737-743.	1.2	33
199	Complications from Surgeries Related to Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 16.	1.3	5
200	Ovarian Cancer Incidence Corrected for Oophorectomy. <i>Diagnostics</i> , 2017, 7, 19.	1.3	10
201	Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 507.	1.8	32
202	Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs. <i>Oncology Research</i> , 2017, 25, 1617-1624.	0.6	21

#	ARTICLE	IF	CITATIONS
203	Case of Ovarian Cancer in a Woman with Undiagnosed Gravesâ€™ Disease: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017, 10, 452-454.	0.3	0
204	A multiplex platform for the identification of ovarian cancer biomarkers. <i>Clinical Proteomics</i> , 2017, 14, 34.	1.1	25
205	Upregulation of microRNAâ€™18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer. <i>Oncology Letters</i> , 2017, 14, 5631-5637.	0.8	9
206	A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. <i>Oncotarget</i> , 2017, 8, 19125-19136.	0.8	6
207	Hedgehog signaling pathway regulates ovarian cancer invasion and migration via adhesion molecule CD24. <i>Journal of Cancer</i> , 2017, 8, 786-792.	1.2	47
208	Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 9660-9671.	0.8	28
209	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
210	Identification of circulating microRNAs as diagnostic biomarkers for ovarian cancer: A pooled analysis of individual studies. <i>International Journal of Biological Markers</i> , 2018, 33, 379-388.	0.7	5
211	ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2. <i>Cancer Letters</i> , 2018, 427, 9-17.	3.2	35
212	Synthetic biology-based cellular biomedical tattoo for detection of hypercalcemia associated with cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	44
213	Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway. <i>Life Sciences</i> , 2018, 202, 188-194.	2.0	28
214	Psychiatric comorbidities among ovarian cancer survivors in South Korea: A nationwide populationâ€™based, longitudinal study. <i>Psycho-Oncology</i> , 2018, 27, 1021-1026.	1.0	12
215	JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. <i>Oncology Letters</i> , 2018, 15, 5772-5780.	0.8	38
216	The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e587-e594.	1.1	4
217	Single-gene prognostic signatures for advanced stage serous ovarian cancer based on 1257 patient samples. <i>Molecular Omics</i> , 2018, 14, 103-108.	1.4	0
218	Ovarian Cancer Knowledge in Women and Providers Following Education with Inside Knowledge Campaign Materials. <i>Journal of Cancer Education</i> , 2018, 33, 1285-1293.	0.6	11
219	<i>AFAP1â€™AS1</i>: A novel oncogenic long nonâ€™coding RNA in human cancers. <i>Cell Proliferation</i> , 2018, 51, .	2.4	57
220	A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 51-58.	1.2	13

#	ARTICLE	IF	CITATIONS
221	Perineal Talc Use and Ovarian Cancer. <i>Epidemiology</i> , 2018, 29, 41-49.	1.2	57
222	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience. <i>International Journal of Hyperthermia</i> , 2018, 34, 564-569.	1.1	12
223	Rac GTPase activating protein 1 promotes oncogenic progression of epithelial ovarian cancer. <i>Cancer Science</i> , 2018, 109, 84-93.	1.7	43
224	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
225	Screening for Ovarian Cancer. , 2018, , .		0
226	Biological Activity of Resveratrol on an Ovarian Cancer Cell. , 2018, , 231-244.		0
227	Survival rates among women with ovarian cancers diagnosed in the area of Podkarpacie province in the years 1990â€”2015. <i>Wspolczesna Onkologia</i> , 2018, 22, 151-157.	0.7	0
228	Potential clinical applications of circulating cell-free DNA in ovarian cancer patients. <i>Expert Reviews in Molecular Medicine</i> , 2018, 20, e6.	1.6	20
229	Downregulation of TGF-Î²1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling. <i>Biological Research</i> , 2018, 51, 58.	1.5	10
230	Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 21-30.	1.0	35
231	STON2 negatively modulates stem-like properties in ovarian cancer cells via DNMT1/MUC1 pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 305.	3.5	23
232	The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review. <i>Oncology Reviews</i> , 2018, 12, 346.	0.8	6
233	An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance. <i>Frontiers in Immunology</i> , 2018, 9, 757.	2.2	7
234	Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. <i>BMC Cancer</i> , 2018, 18, 922.	1.1	10
235	Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients. <i>Journal of Ovarian Research</i> , 2018, 11, 85.	1.3	21
236	DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway. <i>Journal of Ovarian Research</i> , 2018, 11, 90.	1.3	18
237	Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells. <i>International Journal of Oncology</i> , 2018, 53, 855-865.	1.4	7
238	Gene microarray analysis of lncRNA and mRNA expression profiles in patients with highâ€”grade ovarian serous cancer. <i>International Journal of Molecular Medicine</i> , 2018, 42, 91-104.	1.8	17

#	ARTICLE	IF	CITATIONS
239	Intraoperative Raman-Guided Chemo-Photothermal Synergistic Therapy of Advanced Disseminated Ovarian Cancers. <i>Small</i> , 2018, 14, e1801022.	5.2	47
240	Establishment and Characterization of a Highly Metastatic Ovarian Cancer Cell Line. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	6
241	Expression of TBC1D16 Is Associated with Favorable Prognosis of Epithelial Ovarian Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2018, 245, 141-148.	0.5	14
242	Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells. <i>Oncology Letters</i> , 2018, 16, 905-909.	0.8	7
243	Naringin inhibits ovarian tumor growth by promoting apoptosis: An <i>in vivo</i> study. <i>Oncology Letters</i> , 2018, 16, 59-64.	0.8	13
245	Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. <i>Biomaterials</i> , 2018, 182, 114-126.	5.7	44
246	Core-shell nanoparticles for cancer imaging and therapy. , 2018, , 143-175.		6
247	Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. <i>Gynecologic Oncology</i> , 2018, 150, 460-465.	0.6	100
248	Anti-cancer effects of <i>Kaempferia parviflora</i> on ovarian cancer SKOV3 cells. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 178.	3.7	43
249	Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. <i>Journal of Ovarian Research</i> , 2018, 11, 20.	1.3	48
250	Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2831-2841.	1.0	36
251	Neoadjuvant Chemotherapy Treatment Modifications in Ovarian Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 17-20.	0.6	3
252	Augmented cytotoxic effects of paclitaxel by curcumin induced overexpression of folate receptor-1 for enhanced targeted drug delivery in HeLa cells. <i>Phytomedicine</i> , 2019, 56, 279-285.	2.3	23
253	The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. <i>European Journal of Health Economics</i> , 2019, 20, 135-147.	1.4	15
254	SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway. <i>Journal of Translational Medicine</i> , 2019, 17, 259.	1.8	43
255	Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1106.	1.7	30
256	The prevalence, associated factors for bone metastases development and prognosis in newly diagnosed ovarian cancer: a large population based real-world study. <i>Journal of Cancer</i> , 2019, 10, 3133-3139.	1.2	23
257	Inhibition LC3B can increase chemosensitivity of ovarian cancer cells. <i>Cancer Cell International</i> , 2019, 19, 199.	1.8	20

#	ARTICLE	IF	CITATIONS
258	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. <i>BMC Cancer</i> , 2019, 19, 618.	1.1	153
259	Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform. <i>Journal of Controlled Release</i> , 2019, 307, 292-301.	4.8	9
260	Matrine inhibits the development and progression of ovarian cancer by repressing cancer associated phosphorylation signaling pathways. <i>Cell Death and Disease</i> , 2019, 10, 770.	2.7	46
261	Pre-diagnosis body mass index, physical activity and ovarian cancer mortality. <i>Gynecologic Oncology</i> , 2019, 155, 105-111.	0.6	11
262	Co-expression of CD44/MyD88 is a poor prognostic factor in advanced epithelial ovarian cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 91-91.	0.7	6
263	(3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3K/Ā³. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 599-606.	1.1	1
264	The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer. <i>ChemMedChem</i> , 2019, 14, 1810-1827.	1.6	5
265	Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis. <i>International Journal of Oncology</i> , 2019, 54, 1719-1733.	1.4	78
266	<p>LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6297-6307.	1.0	65
267	Comparison of efficacy of robotic surgery, laparoscopy, and laparotomy in the treatment of ovarian cancer: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 162.	0.8	11
268	LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4. <i>Biomedicine and Pharmacotherapy</i> , 2019, 119, 109431.	2.5	16
269	Identification of a 3â€™mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3. <i>Oncology Letters</i> , 2019, 18, 3545-3552.	0.8	5
270	Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1280-1284.	1.2	7
271	Detecting recurrent ovarian cancer: revisit the values of whole-body CT and serum CA 125 levels. <i>Acta Radiologica</i> , 2019, 60, 1360-1366.	0.5	6
272	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019, 12, 9.	1.3	83
273	La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 247, 59-67.	0.5	14
274	Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. <i>EBioMedicine</i> , 2019, 40, 422-431.	2.7	10
275	SMYD3 promotes epithelial ovarian cancer metastasis by downregulating p53 protein stability and promoting p53 ubiquitination. <i>Carcinogenesis</i> , 2019, 40, 1492-1503.	1.3	11

#	ARTICLE	IF	CITATIONS
276	MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation. <i>International Journal of Oncology</i> , 2019, 54, 1833-1842.	1.4	7
277	Senescence-related deterioration of intercellular junctions in the peritoneal mesothelium promotes the transmesothelial invasion of ovarian cancer cells. <i>Scientific Reports</i> , 2019, 9, 7587.	1.6	14
278	Transforming growth factor β /miR-143/3p/cystatin B axis is a therapeutic target in human ovarian cancer. <i>International Journal of Oncology</i> , 2019, 55, 267-276.	1.4	9
279	PARP Inhibitors in Ovarian Cancer: The Route to α -Thalassaemia Diagnostics, 2019, 9, 55.	1.3	52
280	Association of excision repair cross-complimentary group 1 gene polymorphisms with breast and ovarian cancer susceptibility. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 15635-15647.	1.2	4
281	Icariin enhances the chemosensitivity of cisplatin-resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway. <i>International Journal of Oncology</i> , 2019, 54, 1933-1942.	1.4	16
282	Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 100-129.	2.4	28
283	Palmitine from Unexplored <i>Rutidea parviflora</i> Showed Cytotoxicity and Induction of Apoptosis in Human Ovarian Cancer Cells. <i>Toxins</i> , 2019, 11, 237.	1.5	10
284	MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. <i>International Journal of Oncology</i> , 2019, 54, 1771-1784.	1.4	31
285	Molecular Basis Supporting the Association of Talcum Powder Use With Increased Risk of Ovarian Cancer. <i>Reproductive Sciences</i> , 2019, 26, 1603-1612.	1.1	15
286	miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12618-12627.	1.2	34
287	Menopausal hormone therapy in the cancer survivors. <i>Journal of the Korean Medical Association</i> , 2019, 62, 160.	0.1	0
288	Encapsulated lanthanum strontium manganese oxide in mesoporous silica shell: Potential for cancer treatment by hyperthermia therapy. <i>Journal of Alloys and Compounds</i> , 2019, 790, 433-446.	2.8	14
289	E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 161.	1.3	72
290	Mining Featured Biomarkers Linked with Epithelial Ovarian Cancer Based on Bioinformatics. <i>Diagnostics</i> , 2019, 9, 39.	1.3	3
291	HLA-G 3' untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 5407.	1.6	18
292	Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. <i>Journal of Biotechnology</i> , 2019, 297, 58-65.	1.9	32
293	Photoacoustic Flow System for the Detection of Ovarian Circulating Tumor Cells Utilizing Copper Sulfide Nanoparticles. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 1553-1560.	2.6	11

#	ARTICLE	IF	CITATIONS
294	CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression. <i>Cell Structure and Function</i> , 2019, 44, 21-28.	0.5	16
295	Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. <i>OncoImmunology</i> , 2019, 8, e1528411.	2.1	16
296	Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles. <i>Theranostics</i> , 2019, 9, 778-795.	4.6	82
297	Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 897-906.	1.0	23
298	Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125. <i>Journal of Ovarian Research</i> , 2019, 12, 114.	1.3	12
299	Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease. <i>Cancers</i> , 2019, 11, 1887.	1.7	28
300	Prolonged stabilization of platinum-refractory ovarian cancer in a single patient undergoing long-term Mistletoe extract treatment. <i>Medicine (United States)</i> , 2019, 98, e14536.	0.4	5
301	Knockdown of long noncoding RNA-taurine-upregulated gene 1 inhibits tumor angiogenesis in ovarian cancer by regulating leucine-rich ß-2-glycoprotein-1. <i>Anti-Cancer Drugs</i> , 2019, 30, 562-570.	0.7	15
302	Intrauterine Device Use and Ovarian Cancer Risk. <i>Obstetrics and Gynecology</i> , 2019, 134, 791-800.	1.2	29
303	Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10057-10075.	1.0	4
304	Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study. <i>Gynecologic Oncology</i> , 2019, 152, 259-264.	0.6	57
305	PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 646-653.	1.0	26
306	Epigenetic therapy for ovarian cancer: promise and progress. <i>Clinical Epigenetics</i> , 2019, 11, 7.	1.8	181
307	Comparison of Conventional Cytology, Liquid-Based Cytology, and Cell Block in the Evaluation of Peritoneal Fluid in Gynecology Malignancies. <i>Acta Cytologica</i> , 2019, 63, 63-72.	0.7	4
308	Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. <i>Cancers</i> , 2019, 11, 32.	1.7	16
309	Upregulation of Circular RNA <i>VPS13C-has-circ-001567</i> Promotes Ovarian Cancer Cell Proliferation and Invasion. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 110-118.	0.7	31
310	Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 681-697.	2.4	102
311	In vitro selection of DNA aptamers recognizing drug-resistant ovarian cancer by cell-SELEX. <i>Talanta</i> , 2019, 194, 437-445.	2.9	35

#	ARTICLE	IF	CITATIONS
312	Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. <i>Journal of Pharmacy Practice</i> , 2019, 32, 219-224.	0.5	4
313	Development of a M cell-targeted microparticulate platform, BSK02, for oral immunization against the ovarian cancer antigen, sperm protein 17. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2019, 107, 29-36.	1.6	11
314	Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. <i>Journal of the National Cancer Institute</i> , 2019, 111, 60-68.	3.0	319
315	Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer. <i>Epigenetics</i> , 2020, 15, 122-133.	1.3	13
316	Identification of folate receptor β (FR β) binding oligopeptides and their evaluation for targeted virotherapy applications. <i>Cancer Gene Therapy</i> , 2020, 27, 785-798.	2.2	9
317	Interleukin-34 expression in ovarian cancer: a possible correlation with disease progression. <i>International Immunology</i> , 2020, 32, 175-186.	1.8	17
318	STAT3 signaling in ovarian cancer: a potential therapeutic target. <i>Journal of Cancer</i> , 2020, 11, 837-848.	1.2	62
319	TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy. <i>Life Sciences</i> , 2020, 241, 117171.	2.0	7
320	LncRNA SNHG15: A new budding star in human cancers. <i>Cell Proliferation</i> , 2020, 53, e12716.	2.4	38
321	A Population-Based Study on Liver Metastases in Women With Newly Diagnosed Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 571671.	1.3	3
322	Expression of p52, a non-canonical NF- κ B transcription factor, is associated with poor ovarian cancer prognosis. <i>Biomarker Research</i> , 2020, 8, 45.	2.8	7
323	Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region. <i>European Journal of Cancer Care</i> , 2020, 29, e13313.	0.7	0
324	Label-Free Electrochemical Immunosensor Based on One-Step Electrochemical Deposition of AuNP-RGO Nanocomposites for Detection of Endometriosis Marker CA 125. <i>ACS Applied Bio Materials</i> , 2020, 3, 7620-7630.	2.3	60
325	Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1977-1986.	0.5	5
326	An Integrated Approach for Ovarian Cancer Classification With the Application of Stochastic Optimization. <i>IEEE Access</i> , 2020, 8, 127866-127882.	2.6	17
327	Where does cellular senescence belong in the pathophysiology of ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2022, 81, 14-23.	4.3	7
328	Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer. <i>Medicine (United States)</i> , 2020, 99, e23329.	0.4	10
330	Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Dereglulation of BCL2/BAX Genes. <i>Molecules</i> , 2020, 25, 3514.	1.7	20

#	ARTICLE	IF	CITATIONS
331	Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. <i>Cancer Cell International</i> , 2020, 20, 373.	1.8	52
332	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 703.	1.1	22
333	The Prognostic Value of the Chromobox Family in Human Ovarian Cancer. <i>Journal of Cancer</i> , 2020, 11, 5198-5209.	1.2	15
334	ELFN1-AS1 accelerates cell proliferation, invasion and migration via regulating miR-497-3p/CLDN4 axis in ovarian cancer. <i>Bioengineered</i> , 2020, 11, 872-882.	1.4	40
335	Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers. <i>Biomolecules</i> , 2020, 10, 1481.	1.8	37
336	Development of new medical treatment for epithelial ovarian cancer recurrence. <i>Gland Surgery</i> , 2020, 9, 1149-1163.	0.5	12
337	Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1263.	1.3	13
338	Enhancing Delivery of Small Molecule and Cell Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies. <i>Advanced Therapeutics</i> , 2020, 3, 2000144.	1.6	1
339	CA125 and Ovarian Cancer: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 3730.	1.7	174
340	Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9492.	1.8	28
341	Histological Characteristics and Early-Stage Diagnosis Are Associated With Better Survival in Young Patients With Epithelial Ovarian Cancer: A Retrospective Analysis Based on Surveillance Epidemiology and End Results Database. <i>Frontiers in Oncology</i> , 2020, 10, 595789.	1.3	10
342	The anti-tumorigenic effect of ellagic acid in SKOV3 ovarian cancer cells entails activation of autophagy mediated by inhibiting Akt and activating AMPK. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1611-1621.	0.9	10
343	A critical review of talc and ovarian cancer. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2020, 23, 183-213.	2.9	9
344	FAT4 silencing promotes epithelial-to-mesenchymal transition and invasion via regulation of YAP and β -catenin activity in ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 374.	1.1	19
345	pH- and acoustic-responsive platforms based on perfluoropentane-loaded protein nanoparticles for ovarian tumor-targeted ultrasound imaging and therapy. <i>Nanoscale Research Letters</i> , 2020, 15, 31.	3.1	13
346	Rapid intraoperative diagnosis of gynecological cancer by ATR-FTIR spectroscopy of fresh tissue biopsy. <i>Journal of Biophotonics</i> , 2020, 13, e202000114.	1.1	8
347	Role of Folic Acid in the Therapeutic Action of Nanostructured Porous Silica Functionalized with Organotin(IV) Compounds against Different Cancer Cell Lines. <i>Pharmaceutics</i> , 2020, 12, 512.	2.0	14
348	Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells. <i>Dose-Response</i> , 2020, 18, 155932582092673.	0.7	8

#	ARTICLE	IF	CITATIONS
349	RF hyperthermia by encapsulated Fe ₃ O ₄ nanoparticles induces cancer cell death via time-dependent caspase-3 activation. <i>Nanomedicine</i> , 2020, 15, 355-379.	1.7	11
350	Magnetic bead-amplified voltammetric detection for carbohydrate antigen 125 with enzyme labels using aptamer-antigen-antibody sandwiched assay. <i>Sensors and Actuators B: Chemical</i> , 2020, 312, 127985.	4.0	38
351	Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. <i>Cancer Prevention Research</i> , 2020, 13, 241-252.	0.7	44
352	CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. <i>Oncogene</i> , 2020, 39, 3965-3979.	2.6	27
353	Heat Shock Protein 60 (HSP60) Serves as a Potential Target for the Sensitization of Chemoresistant Ovarian Cancer Cells. <i>Reproductive Sciences</i> , 2020, 27, 1030-1036.	1.1	7
354	Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. <i>Clinical Therapeutics</i> , 2020, 42, 1192-1209.e12.	1.1	9
355	TRPV1 Antagonist DWPO5195 Induces ER Stress-Dependent Apoptosis through the ROS-p38-CHOP Pathway in Human Ovarian Cancer Cells. <i>Cancers</i> , 2020, 12, 1702.	1.7	19
356	Physical activity and exercise in women with ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2020, 158, 803-811.	0.6	27
357	The Prevalence and associated Factors for Liver Metastases, Development and Prognosis in newly diagnosed Epithelial Ovarian Cancer: A large Population-Based Study from the SEER Database. <i>Journal of Cancer</i> , 2020, 11, 4861-4869.	1.2	2
358	ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy. <i>Cell Death and Disease</i> , 2020, 11, 137.	2.7	50
359	Ovarian Cancer Targeted Theranostics. <i>Frontiers in Oncology</i> , 2019, 9, 1537.	1.3	27
360	Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer. <i>International Journal of Hyperthermia</i> , 2020, 37, 101-109.	1.1	7
361	L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population. <i>Cancers</i> , 2020, 12, 217.	1.7	23
362	Mitochondria-targeting zeolitic imidazole frameworks to overcome platinum-resistant ovarian cancer. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 189, 110837.	2.5	13
364	Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 319.	1.3	44
365	Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. <i>Stem Cell Reports</i> , 2020, 14, 717-729.	2.3	105
366	Prognostic significance of lymphocyte monocyte ratio in patients with ovarian cancer. <i>Medicine (United States)</i> , 2020, 99, e19638.	0.4	11
367	microRNAs as biomarkers of ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 373-385.	1.1	14

#	ARTICLE	IF	CITATIONS
368	The role of the CDCA gene family in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 190-190.	0.7	29
369	Evaluation of a novel ovarian cancer-specific fluorescent antibody probe for targeted near-infrared fluorescence imaging. <i>World Journal of Surgical Oncology</i> , 2020, 18, 66.	0.8	6
370	What do partners of patients with ovarian cancer need from the healthcare system? An examination of caregiving experiences in the healthcare setting and reported distress. <i>Supportive Care in Cancer</i> , 2021, 29, 1213-1223.	1.0	9
371	Association of genetic variants in the 3' untranslated region of the mesothelin (<i>MSLN</i>) gene with ovarian carcinoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2021, 35, e22637.	1.4	8
372	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. <i>Journal of Cancer</i> , 2021, 12, 38-53.	1.2	36
373	Nanoparticles loading porphyrin sensitizers in improvement of photodynamic therapy for ovarian cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 33, 102156.	1.3	20
374	PHLDA1 Modulates the Endoplasmic Reticulum Stress Response and is required for Resistance to Oxidative Stress-induced Cell Death in Human Ovarian Cancer Cells. <i>Journal of Cancer</i> , 2021, 12, 5486-5493.	1.2	8
375	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	1.9	9
376	Palliative Care of Patients with Ovarian Cancer. , 2021, , 243-249.		0
377	Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway. <i>International Journal of Biological Sciences</i> , 2021, 17, 574-588.	2.6	15
378	Nanotechnology advances in ovarian cancer. , 2021, , 105-128.		1
379	Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP. <i>Journal of Cancer</i> , 2021, 12, 1660-1668.	1.2	13
380	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. , 2021, , 49-69.		0
381	Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis. <i>Journal of Ovarian Research</i> , 2021, 14, 30.	1.3	15
382	Incidence of and risk factors associated with lung metastases in newly diagnosed epithelial ovarian cancer with a look on prognosis after diagnosis: a population-based cohort study of the SEER database. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1007-1020.	0.8	4
383	The diagnostic performance of the Gynecologic Imaging Reporting and Data System (GI-RADS) in adnexal masses. <i>Annals of Translational Medicine</i> , 2021, 9, 398-398.	0.7	5
384	<i>E2F5</i> Promotes the Malignancy of Ovarian Cancer Via the Regulation of Hippo and Wnt Pathways. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 179-186.	0.3	4
385	Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo. <i>Biomedicines</i> , 2021, 9, 330.	1.4	3

#	ARTICLE	IF	CITATIONS
386	Selective mediation of ovarian cancer SKOV3 cells death by pristine carbon quantum dots/Cu ₂ O composite through targeting matrix metalloproteinases, angiogenic cytokines and cytoskeleton. <i>Journal of Nanobiotechnology</i> , 2021, 19, 68.	4.2	23
387	A review of Tumor Treating Fields and their future implication in treatment of platinum resistant ovarian cancer. <i>Obstetrics & Gynecology International Journal</i> , 2021, 12, .	0.0	0
388	Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3495.	1.8	9
389	Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	3
390	Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer. <i>Journal of Controlled Release</i> , 2021, 332, 448-459.	4.8	36
391	Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study. <i>Iranian Journal of Pathology</i> , 2021, 16, 109-118.	0.2	1
392	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	2.9	7
393	Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease. <i>European Journal of Pharmacology</i> , 2021, 898, 173972.	1.7	10
394	Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study. <i>BMC Cancer</i> , 2021, 21, 609.	1.1	11
395	MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor- β 1 Canonical Pathway. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6502.	1.8	6
396	M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 161, 681-686.	0.6	5
397	YWHAE as an HE4 interacting protein can influence the malignant behaviour of ovarian cancer by regulating the PI3K/AKT and MAPK pathways. <i>Cancer Cell International</i> , 2021, 21, 302.	1.8	12
398	Altered Expression of ESR1, ESR2, PELP1 and c-SRC Genes Is Associated with Ovarian Cancer Manifestation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6216.	1.8	11
399	Preoperative Prediction of Metastasis for Ovarian Cancer Based on Computed Tomography Radiomics Features and Clinical Factors. <i>Frontiers in Oncology</i> , 2021, 11, 610742.	1.3	18
400	TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells. <i>Journal of Ovarian Research</i> , 2021, 14, 82.	1.3	13
401	Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 879.	0.8	6
402	Research Status and Progress of Nutritional Support Therapy for Ovarian Cancer. <i>Nutrition and Cancer</i> , 2022, 74, 1519-1526.	0.9	2
403	Long Noncoding RNA CTD-2589M5.4 Inhibits Ovarian Cancer Cell Proliferation, Migration, and Invasion Via Downregulation of the Extracellular Matrix- α 2 Receptor Interaction Pathway. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	0.7	3

#	ARTICLE	IF	CITATIONS
404	Ambient air pollution and ovarian cancer survival in California. <i>Gynecologic Oncology</i> , 2021, 163, 155-161.	0.6	11
405	The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2123-2129.	1.0	1
406	The Role of microRNA Let-7d in Female Malignancies and Diseases of the Female Reproductive Tract. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7359.	1.8	12
407	Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay. <i>Biomedicines</i> , 2021, 9, 1028.	1.4	2
408	Ovarian cancer: epigenetics, drug resistance, and progression. <i>Cancer Cell International</i> , 2021, 21, 434.	1.8	33
409	An Investigation of the Effect of Attachment on Distress among Partners of Patients with Ovarian Cancer and Their Relationship with the Cancer Care Providers. <i>Current Oncology</i> , 2021, 28, 2950-2960.	0.9	2
410	A transcription factor that promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of ovarian cancer cells and its possible mechanisms. <i>BioMedical Engineering OnLine</i> , 2021, 20, 83.	1.3	6
411	Molecular Functions of Hydrogen Sulfide in Cancer. <i>Pathophysiology</i> , 2021, 28, 437-456.	1.0	20
412	LncRNA <i>SRNA</i> mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition. <i>Bioscience Reports</i> , 2021, 41, .	1.1	13
414	Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 553-561.	1.2	11
415	Association of vitamin E on the risk of ovarian cancer: a meta-analysis. <i>Bioscience Reports</i> , 2019, 39, .	1.1	14
416	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , 2013, 123, 3740-50.	3.9	46
417	Ovarian Cancer: A Bioepidemiological Approach. , 2013, , 331-350.		1
418	POZ/BTB and AT-Hook-Containing Zinc Finger Protein 1 (PATZ1) Suppresses Progression of Ovarian Cancer and Serves as an Independent Prognosis Factor. <i>Medical Science Monitor</i> , 2018, 24, 4262-4270.	0.5	4
419	Dexmedetomidine Regulates Proliferation, Apoptosis, Migration, and Invasion in Ovarian Cancer Cells via MiR-155-HIF-1 α Axis. <i>Medical Science Monitor</i> , 2019, 25, 10164-10172.	0.5	11
420	Serum Protein Profile at Remission Can Accurately Assess Therapeutic Outcomes and Survival for Serous Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e78393.	1.1	14
421	Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0155495.	1.1	58
422	Increased expression of protein kinase CK2 α correlates with poor patient prognosis in epithelial ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0174037.	1.1	12

#	ARTICLE	IF	CITATIONS
423	Intraperitoneal Treatment in Ovarian Cancer: The Gynecologic Oncology Group Perspective in 2012. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 345-348.	1.8	4
424	Andrographolide as a therapeutic agent against breast and ovarian cancers. Open Life Sciences, 2019, 14, 462-469.	0.6	16
425	The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocrine-Related Cancer, 2018, 25, R663-R685.	1.6	57
426	Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells. Aging, 2020, 12, 11042-11060.	1.4	9
427	FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription. Oncotarget, 2016, 7, 47985-47997.	0.8	48
428	Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer. Oncotarget, 2016, 7, 49710-49721.	0.8	8
429	MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Oncotarget, 2016, 7, 80633-80654.	0.8	48
430	An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. Oncotarget, 2017, 8, 53432-53449.	0.8	25
431	Constructing an ovarian cancer metastasis index by dissecting medical records. Oncotarget, 2017, 8, 102212-102222.	0.8	4
432	Novel cooperative pathway of c-Myc and Furin, a pro-protein convertase, in cell proliferation as a therapeutic target in ovarian cancers. Oncotarget, 2018, 9, 3483-3496.	0.8	7
433	Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget, 2014, 5, 8703-8715.	0.8	26
434	Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. Oncotarget, 2018, 9, 19662-19674.	0.8	11
435	Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers. Oncotarget, 2018, 9, 27514-27524.	0.8	13
436	IGHG1 promotes motility likely through epithelial-mesenchymal transition in ovarian cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 282-290.	0.7	9
437	Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors. Current Cancer Drug Targets, 2019, 19, 179-188.	0.8	24
438	Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites. Bio-protocol, 2017, 7, e2219.	0.2	5
439	Global scenario on ovarian cancer – Its dynamics, relative survival, treatment, and epidemiology. , 0, 2, 17-25.		15
440	miR4435 promotes proliferation and inhibits apoptosis of cancer cells in ovarian carcinoma by upregulating ROCK2. Oncology Letters, 2020, 19, 1305-1309.	0.8	5

#	ARTICLE	IF	CITATIONS
441	Glucose restriction combined with chemotherapy decreases telomere length and cancer antigenâ€125 secretion in ovarian carcinoma. <i>Oncology Letters</i> , 2020, 19, 1338-1350.	0.8	1
442	Pharmacokinetic evaluation and antitumor potency of liposomal nanoparticle encapsulated cisplatin targeted to CD24â€positive cells in ovarian cancer. <i>Oncology Letters</i> , 2020, 19, 1872-1880.	0.8	7
443	Role of Insulin-like Growth Factor, Insulin-like Growth Factor Receptors, and Insulin-like Growth Factor-binding Proteins in Ovarian Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2017, 38, 198-206.	0.1	14
444	Isolated fluorodeoxyglucose avid right pleural deposits/effusion on an F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with ovarian cancer â€“ Are they almost certainly metastatic? An extrapolation of atypical meigs' syndrome. <i>Indian Journal of Nuclear Medicine</i> , 2019, 34, 42.	0.1	1
445	Burden of gynaecological cancers in developing countries. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 1.	0.5	17
446	Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 457.	0.6	19
447	Prognostic Factors among Brain Metastases in Newly Diagnosed Ovary Cancer: A Large Real-world Study. <i>Journal of Cancer</i> , 2020, 11, 4625-4640.	1.2	6
448	Rapid Detection of Ovarian Cancer from Immunized Serum Using a Quartz Crystal Microbalance Immunosensor. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3423-3426.	0.5	8
449	Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 8539-8548.	0.5	79
450	Pre-Operative Evaluation of Ovarian Tumors by Risk of Malignancy Index, CA125 and Ultrasound. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 2929-2932.	0.5	18
451	Ovarian Cancer, Early Primary Disease. <i>UNIPA Springer Series</i> , 2021, , 843-859.	0.1	0
452	The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10817.	1.8	5
453	Gemogenovatu cel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 459-464.	0.6	11
454	Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro. <i>Cellular and Molecular Biology Letters</i> , 2021, 26, 44.	2.7	16
455	MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-25.	0.6	13
456	Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene. <i>Cureus</i> , 2021, 13, e18691.	0.2	0
457	Management of Recurrent or Persistent Ovarian Cancer. , 0, , .		0
459	Ovarian Cancer Prevention. , 2014, , 557-591.		2

#	ARTICLE	IF	CITATIONS
460	Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1 α pathway in human ovarian cancer in vitro. <i>Journal of Ovarian Research</i> , 2014, 7, 115.	1.3	16
461	Accuracy of Magnetic Resonance Imaging in Pretreatment Lymph Node Assessment for Gynecological Malignancies. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4705-4709.	0.5	1
462	Recurrent ovarian cancer. , 2015, , 303-318.		0
463	Bilious pleural effusion from metastatic serous adenocarcinoma of the ovary: A case report. <i>Journal of Case Reports and Images in Medicine</i> , 2016, 2, 1.	0.0	0
464	Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. <i>Universa Medicina</i> , 2016, 35, 165.	0.1	0
465	Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients. <i>Universa Medicina</i> , 2016, 35, 165.	0.1	0
466	Echography in the estimation of the extent of ovarian cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2017, 6, 14.	0.0	2
467	Efficacy of reamberin in the correction of lipid peroxidation processes in the plasma of patients with ovarian cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 40.	0.0	8
468	Epithelial Ovarian Cancer Prevention. , 2019, , 677-722.		1
469	Serum Human Epididymus Protein-4 (HE4) as a Biomarker in Ovarian Cancer and its Comparison with CA-125 in Benign and Malignant Cases. <i>Indian Journal of Medical Biochemistry</i> , 2019, 23, 242-246.	0.1	0
470	In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery. <i>Journal of the Turkish German Gynecology Association</i> , 2019, 20, 31-36.	0.2	1
471	High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma. <i>Oncology Letters</i> , 2019, 18, 4900-4906.	0.8	2
472	PNMA5 knockdown suppresses the proliferation, invasion, and metastasis of epithelial ovarian cancer cells. <i>Translational Cancer Research</i> , 2020, 9, 3691-3702.	0.4	1
473	A Single Centre Randomised Control Study to Assess the Impact of Pre-Operative Carbohydrate Loading on Women Undergoing Major Surgery for Epithelial Ovarian Cancer. <i>Cureus</i> , 2020, 12, e10169.	0.2	0
474	Possible applications of salvianolic acid B against different cancers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 218-238.	0.5	5
475	The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers. <i>Biomedicines</i> , 2021, 9, 1554.	1.4	2
477	Reflections on the Role of Malat1 in Gynecological Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 13489-13500.	0.9	9
478	Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 765458.	1.3	18

#	ARTICLE	IF	CITATIONS
479	Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study. <i>Cancer Communications</i> , 2021, 41, 1373-1386.	3.7	6
480	A CT-based radiomics nomogram for predicting early recurrence in patients with high-grade serous ovarian cancer. <i>European Journal of Radiology</i> , 2021, 145, 110018.	1.2	21
481	Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017. <i>Gynecologic Oncology</i> , 2022, 164, 98-104.	0.6	5
482	Development and validation of a nomogram to predict synchronous lung metastases in patients with ovarian cancer: a large cohort study. <i>Bioscience Reports</i> , 2020, 40, .	1.1	5
484	Stress induced premature senescence: a new culprit in ovarian tumorigenesis?. <i>Indian Journal of Medical Research</i> , 2014, 140 Suppl, S120-9.	0.4	7
485	Retinoic acid aliphatic amide inhibits the AMPK-HIF-1 α pathway in human ovarian cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6416-24.	0.5	0
486	Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15719-28.	0.5	28
487	MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian cancer. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 1748-55.	0.0	16
488	Early and late onset complications of gynaecologic surgery: a multimodality imaging approach. <i>Facts, Views & Vision in ObGyn</i> , 2017, 9, 5-14.	0.5	0
489	Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. <i>P and T</i> , 2018, 43, 549-556.	1.0	9
490	LncRNA PCAT-1 plays an oncogenic role in epithelial ovarian cancer by modulating cyclinD1/CDK4 expression. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 2148-2156.	0.5	7
491	Silencing CCAT2 inhibited proliferation and invasion of epithelial ovarian carcinoma cells by regulating Wnt signaling pathway. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11771-11778.	0.5	1
492	A prognosis-predictive nomogram of ovarian cancer with two immune-related genes: and. <i>Oncology Letters</i> , 2020, 20, 204.	0.8	3
493	Construction and validation of a novel aging-related gene signature and prognostic nomogram for predicting the overall survival in ovarian cancer. <i>Cancer Medicine</i> , 2021, , .	1.3	9
494	Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database. <i>Frontiers in Medicine</i> , 2021, 8, 756401.	1.2	7
495	Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma. <i>Aging</i> , 2021, 13, 24686-24709.	1.4	4
496	Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 993-1000.	2.2	4
497	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287.	0.6	68

#	ARTICLE	IF	CITATIONS
498	Quantitative biophysical metrics for rapid evaluation of ovarian cancer metastatic potential. <i>Molecular Biology of the Cell</i> , 2022, 33, mbcE21080419.	0.9	4
499	Ovarian cancer and KiSS-1 gene expression: A consideration of the use of Kisspeptin plus Kisspeptin aptamers in diagnostics and therapy. <i>European Journal of Pharmacology</i> , 2022, 917, 174752.	1.7	2
500	Determination of chemoresistance in ovarian cancer by simultaneous quantification of exosomes and exosomal cisplatin with surface enhanced Raman scattering. <i>Sensors and Actuators B: Chemical</i> , 2022, 354, 131237.	4.0	8
501	A prognosisâ€predictive nomogram of ovarian cancer with two immuneâ€related genes: CDC20B and PNPLA5. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	7
502	A clinical model to predict the risk of liver metastases in newly diagnosed ovarian cancer: a population-based study. <i>Translational Cancer Research</i> , 2020, 9, 7044-7053.	0.4	2
503	Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 793024.	1.3	3
504	Ovarian Carcinoma Presenting With a Large Cervical Mass. <i>Cureus</i> , 2022, 14, e20994.	0.2	1
505	Quantitative analysis of the MRI features in the differentiation of benign, borderline, and malignant epithelial ovarian tumors. <i>Journal of Ovarian Research</i> , 2022, 15, 13.	1.3	4
506	A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24232.	0.9	3
507	NGAL/MMP-9 as a biomarker for epithelial ovarian cancer: A caseâ€control diagnostic accuracy study. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2022, 10, 25.	0.3	2
508	Urinary biomarkers for the detection of ovarian cancer: a systematic review. <i>Carcinogenesis</i> , 2022, 43, 311-320.	1.3	2
509	RP5-1148A21.3 (lncRP5) exerts oncogenic function in human ovarian carcinoma. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, 54, 209-219.	0.9	2
510	CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 798680.	1.3	10
511	The design and discovery of topoisomerase I inhibitors as anticancer therapies. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 581-601.	2.5	15
512	Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. <i>The Lancet Digital Health</i> , 2022, 4, e179-e187.	5.9	37
513	Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells. <i>Journal of the American Society for Mass Spectrometry</i> , 2022, 33, 242-250.	1.2	5
514	Cisplatin Resistance in Ovarian Cancer: Classical Outlook and Newer Perspectives. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 1993-2005.	0.2	4
515	Association Between Pre-diagnostic Dietary Supplements Intake and Ovarian Cancer Survival: Findings From a Prospective Cohort Study in Chinese Women. <i>Frontiers in Nutrition</i> , 2021, 8, 758178.	1.6	10

#	ARTICLE	IF	CITATIONS
516	Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1335.	1.1	13
517	The risk of distant metastases in patients with gynecologic cancers after surgery: a population-based study. <i>Aging</i> , 2021, 13, 25846-25858.	1.4	2
528	CT review of ovarian fibrothecoma. <i>British Journal of Radiology</i> , 2022, 95, 20210790.	1.0	0
529	Characterising differences in red blood cell usage patterns between healthcare sectors in South Africa: 2014-2019.. <i>Blood Transfusion</i> , 2021, , .	0.3	0
530	Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. <i>Cancers</i> , 2022, 14, 2362.	1.7	5
531	Expression and purification of recombinant human CCL5 and its biological characterization. <i>Protein Journal</i> , 2022, 41, 337-344.	0.7	1
532	Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting. <i>Medicina (Lithuania)</i> , 2022, 58, 649.	0.8	3
533	And p53 in epithelial immunohisto- chemical expression of Forkhead Box (FOX) A1 ovarian cancer. <i>Clinical Journal of Obstetrics and Gynecology</i> , 2022, 5, 061-066.	0.1	0
534	Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	2
535	A Three-Dimensional Culture-Based Assay to Detect Early Stages of Vasculogenic Mimicry in Ovarian Cancer Cells. <i>Methods in Molecular Biology</i> , 2022, , 53-60.	0.4	3
536	Advances in Exosomal microRNAs and Proteins in Ovarian Cancer Diagnosis, Prognosis, and Treatment. <i>Current Molecular Medicine</i> , 2023, 23, 509-520.	0.6	2
537	Mutation analysis of circulating tumor DNA and paired ascites and tumor tissues in ovarian cancer. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	5
538	Coinage Metal Compounds With 4-Methoxy-Diphenylphosphane Benzoate Ligand Inhibit Female Cancer Cell Growth. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	2
539	High-quality nursing care on psychological disorder in ovarian cancer during perioperative period: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29849.	0.4	0
540	A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	5
541	Binding of Intracellular Myeloperoxidase to β_1 Integrin Serves as a Mechanism of Survival in Epithelial Ovarian Cancer. <i>Reproductive Sciences</i> , 2023, 30, 291-300.	1.1	1
542	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8125.	1.8	9
543	Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	3

#	ARTICLE	IF	CITATIONS
544	The Role of Inflammasomes in Ovarian Cancer. , 0, , 57-68.		2
545	<i>Ex Vivo</i> assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome. International Journal of Oncology, 2022, 61, .	1.4	1
546	Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. Journal of Ethnopharmacology, 2023, 300, 115728.	2.0	4
547	Tongguanteng Injection Reverses Paclitaxel Resistance Via Upregulation of TAB1 Expression in Ovarian Cancer in Vitro and in Vivo. SSRN Electronic Journal, 0, , .	0.4	0
549	NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 972-980.	2.3	106
550	Hsa_circ_0001445 works as a cancer suppressor via miR-576-5p/SFRP1 axis regulation in ovarian cancer. Cancer Medicine, 2023, 12, 5736-5750.	1.3	4
551	A Machine Learning Approach Using XGBoost Predicts Lung Metastasis in Patients with Ovarian Cancer. BioMed Research International, 2022, 2022, 1-8.	0.9	4
552	Identification of two theranostic biomarker panels for epithelial ovarian cancer. Cytokine, 2023, 161, 156051.	1.4	5
553	Recurrent malignant ovarian adenocarcinoma with central nervous system metastasis successfully treated with paclitaxel, carboplatin, capecitabine, and gemcitabine. Baylor University Medical Center Proceedings, 0, , 1-3.	0.2	0
554	Evaluating the Potential Anticancer Properties of Salvia triloba in Human-Osteosarcoma U2OS Cell Line and Ovarian Adenocarcinoma SKOV3 Cell Line. Applied Sciences (Switzerland), 2022, 12, 11545.	1.3	0
555	Region-Based Segmentation and Classification for Ovarian Cancer Detection Using Convolution Neural Network. Contrast Media and Molecular Imaging, 2022, 2022, 1-12.	0.4	6
556	Pre-Diagnosis Sleep Status and Survival after a Diagnosis of Ovarian Cancer: A Prospective Cohort Study. Journal of Clinical Medicine, 2022, 11, 6914.	1.0	0
557	Potential of histone deacetylase inhibitors for the therapy of ovarian cancer. Frontiers in Oncology, 0, 12, .	1.3	3
558	Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International Journal of Clinical Oncology, 2023, 28, 163-174.	1.0	1
559	miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β2-catenin signaling and autophagy via targeting HMGA2. Cancer Gene Therapy, 2023, 30, 596-607.	2.2	3
561	Loss of CBX2 causes genomic instability and Wnt activation in high grade serous ovarian carcinoma cells. Molecular Carcinogenesis, 2023, 62, 479-492.	1.3	1
562	The Histopathological Patterns of Ovarian Neoplasms in Different Age Groups: A Retrospective Study in a Tertiary Care Center. Cureus, 2022, , .	0.2	1
563	Tumour Markers in Clinical Use. , 2023, , 11-32.		0

#	ARTICLE	IF	CITATIONS
564	Molecular genetic testing in ovarian cancer. Pacific Medical Journal, 2023, , 11-18.	0.0	0
565	Unveiling the gemcitabine drug complexation with cucurbit[n]urils (nâ€™=â€™6â€™8): a computational analysis. Structural Chemistry, 2023, 34, 1869-1882.	1.0	0
566	Dual regulation of Akt and glutathione caused by isoalantolactone effectively triggers human ovarian cancer cell apoptosis. Acta Biochimica Et Biophysica Sinica, 2023, , .	0.9	1
567	A Novel Score Using Lymphocyte-to-Monocyte Ratio in Blood and Malignant Body Fluid for Predicting Prognosis of Patients with Advanced Ovarian Cancer. Cancers, 2023, 15, 2328.	1.7	1
569	Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer. Cancers, 2023, 15, 1172.	1.7	2
570	Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes. Cancers, 2023, 15, 1282.	1.7	2
571	VEGFR3 suppression through miRâ€™1236 inhibits proliferation and induces apoptosis in ovarian cancer via ERK1/2 and AKT signaling pathways. Journal of Cellular Biochemistry, 2023, 124, 674-686.	1.2	5
572	Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. American Journal of Obstetrics and Gynecology, 2023, 229, 93-100.	0.7	0
573	The association of macronutrient quality and its interactions with energy intake with survival among patients with ovarian cancer: results from a prospective cohort study. American Journal of Clinical Nutrition, 2023, 117, 1362-1371.	2.2	2
574	AN UPDATED REVIEW ON OVARIAN CANCER. , 0, , 24-29.		0
575	Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer. British Journal of Cancer, 0, , .	2.9	0
576	Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2/HOâ€™1/NQO1 signaling pathway in ovarian cancer cells. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	7
577	Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer. Journal of Ovarian Research, 2023, 16, .	1.3	1
591	High-Grade Serous Carcinoma. , 2023, , 53-72.		0